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As the global burden of mortality from COVID-19 continues to rise, an understanding
of who is most at risk of adverse outcomes is of paramount importance. Pre-existing
cardiometabolic, renal and respiratory diseases as well as old age are well-established
risk factors associated with disease severity and mortality among patients with
COVID-19. However, mounting evidence also indicates an increased susceptibility to,
and risk of adverse outcomes from COVID-19 in people with schizophrenia, independent
of age and comorbidity. Therefore, elucidating the underlying pathophysiological
mechanisms which may increase the risk of poor outcomes in people with schizophrenia
is of crucial importance. Here, we provide a narrative on the current understanding
of COVID-19 in patients with schizophrenia and propose potential mechanisms which
may link schizophrenia with an increased susceptibility to, and greater risk of adverse
outcomes from COVID-19. Given the existing knowledge gaps, robust clinical and
biological studies are required to further our understanding of some of these underlying
mechanisms, so that effective prevention and treatment strategies for COVID-19 in
patients with schizophrenia can be developed.
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INTRODUCTION
The novel coronavirus disease-2019 (COVID-19), caused by the highly infectious severe acute
respiratory coronavirus 2 (SARS-CoV-2), has led to more than 2 million deaths globally as
of March 2021 (1), and the global mortality continues to rise. The clinical manifestations of
SARS-CoV-2 infection are broad, ranging from asymptomatic or mild flu-like symptoms, through
to fatal outcomes including respiratory syndromes requiring mechanical ventilation, multiorgan
failure and death (2, 3). Epidemiological studies have reported a greater risk of adverse clinical
outcomes of COVID-19 in men, the elderly, and in those with pre-existing comorbidities including
cardiovascular diseases (CVD), diabetes mellitus (DM), renal and respiratory diseases (4). In
addition, a robust body of evidence suggest that the determinants of severity of SARS-CoV-2
infection are more likely to be related to host factors, rather than the viral genetic variation (3).
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Whilst global attention has largely focused on COVID-19
patients with significant physical comorbidities, the clinical
impact of COVID-19 on people with severe mental disorders
(SMD) such as schizophrenia has been relatively overlooked.
Predictors of disease severity in COVID-19 such as CVD, DM,
chronic obstructive pulmonary disease (COPD) and chronic
immune dysregulation are more prevalent in people with
schizophrenia, than the general population (5–11), suggesting
the possibility of a more pronounced severity of COVID-
19 in people with schizophrenia. Furthermore, people with
schizophrenia may also be at increased risk of contracting
COVID-19 due to the chronic nature of their illness, behavioural
factors relating to cognitive impairment and poor risk awareness,
sociodemographic characteristics including homelessness and
congregate housing and the adverse effects of antipsychotics
(12). In line with these observations, emerging epidemiological
evidence suggests that people with schizophrenia could be at
increased risk of COVID-19 and its adverse outcomes (see
Table 1). However, it remains unclear whether schizophrenia
itself independently increases the risk of severe COVID-19
infections or whether concomitant comorbidities and risk factors
may be driving such worse prognosis.
In this article, we aim to: (i) appraise the available
epidemiological evidence of COVID-19 in people with
schizophrenia; and (ii) narratively describe and integrate,
as a hypothesis, the available evidence on the potential
pathophysiological underpinnings that may confer vulnerability
to severe SARS-CoV-2 infection in schizophrenia. Based on
the current understanding of clinical features of the virus, we
hypothesise that people with schizophrenia are at increased
risk of severe SARS-CoV-2 infection and heightened risk of
mortality, irrespective of baseline comorbidities, treatment and
lifestyle factors. Insights into the biological mechanisms that
contribute to to COVID-19 susceptibility and prognosis will be
crucial in development of new therapeutic targets, furthering
our knowledge of tissue tropism, and will also help tailoring
public health strategies relevant to this group of patients. We
recommend that people with schizophrenia should be considered
a priority group in vaccine allocation.
The psychosocial impact of COVID-19 pandemic on people
with schizophrenia has been described elsewhere (12, 19, 20), and
is beyond the scope of this article.
METHODOLOGY
For this article, PubMed and Google Scholar were searched for
published or unpublished articles, up to 18th March, 2021, using
the search terms “schizophrenia,” “psychosis,” “first episode
psychosis,” “SARS-CoV-2,” “COVID-19,” “coronavirus,” “mental
illness,” “mental disorders,” “severe mental illness/disorders,
“obesity,” “antipsychotics,” “inflammation,” “outcome,”
“comorbidities,” “age’, “gender’, “ethnicity,” “mendelian
randomisation,” “neurotropism,” “central nervous system,”
“ACE 2,” “renin-angiotensin system,” “pathophysiology” and a
combination thereof. We incorporated peer-reviewed articles
and two preprint articles. We also referred to related scientific
reports, such as the Care Quality Commission, UK, and Public
Health England guidance on clinically extremely vulnerable
groups (CEV) for vaccine prioritisation. Formal quality
assessment of studies were not undertaken for this hypothesis
article, nor was a systematic review or meta-analysis conducted.
INTERACTION BETWEEN COVID-19 AND
SCHIZOPHRENIA: EPIDEMIOLOGICAL
EVIDENCE
People with schizophrenia are known to suffer from a
higher prevalence of respiratory tract infections than general
population (21–23). The global age-standardized prevalence of
schizophrenia is estimated to be 0.28% (24). The prevalence
of schizophrenia in 7341 Korean patients with COVID-19 was
3.6% (16), over five times higher than the national prevalence of
schizophrenia in Korea (0.66%) (25). Importantly, the prevalence
of schizophrenia in severe COVID-19 was even higher, at 5.4%
(16). In 50,750 patients admitted to hospital for COVID-19 in
France, the prevalence of schizophrenia was 1.6%. (13), which is
60% higher than the lifetime prevalence of schizophrenia in the
West. A retrospective study from US reported a prevalence of 2%
for psychotic disorders in 62,354 patients with COVID-19 (15).
Schizophrenia may confer an inherent risk for COVID-19. A
recent large retrospective cohort study reported that psychotic
disorders (including schizophrenia) could be an independent risk
factor for COVID-19 (Risk ratio RR 1·17 95% CI 1·02–1·33;
p = 0·022), irrespective of physical risk factors for COVID-
19 and duration of psychotic illness (18). A case-control study
from South Korea reported an increased risk of COVID-19
in patients with schizophrenia (odds ratio range, 1.614–1.721)
(16). Similar observations were made in another case-control
study from US, which reported an increased risk of COVID-19
among patients with schizophrenia, after adjusting for potential
confounders (adjusted odds ratio AOR= 7.34, 95%CI: 6.65–8.10,
p < 0.001) (15). There is also some evidence of rapid SARS-
CoV-2 transmission in psychiatry units (26, 27). The heightened
risk may be specific to schizophrenia rather than generalised
across all mental disorders. For instance, a nationwide South
Korean cohort study reported that diagnosis of any mental
illness was not associated with higher rates of SARS-CoV-2
infection (AOR 1.00, 95% CI 0.93–1.08) (14). A recent mendelian
randomisation (MR) study suggests a significant genetic liability
to a combined phenotype of bipolar disorder and schizophrenia
with increased COVID-19 susceptibility, but the effect estimates
were not consistent in multivariate analysis (28). However, this
should be interpreted with caution because of the usage of
small sample size in the early genome-wide association studies
of COVID-19.
Schizophrenia appears to be associated with poorer prognosis
in patients with COVID-19. A French population—based cohort
study has reported a higher odds of mortality among in-patients
with schizophrenia compared with controls [AOR 1.30 [95%
CI, 1.08–1.56], P = 0.0093) (13). Another case-control study
reported that patients with SMD including schizophrenia are
1.3 times more likely to experience severe outcomes (mortality,
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TABLE 1 | COVID-19 outcomes according to pre-existing schizophrenia.
References Article type Study population Prevalence of schizophrenia Outcome Risk
Fond et al. (13) Cohort study 50,750 1.60% In-hospital mortality 1.30 (1.08–1.56)*
Fond et al. (13) Cohort study 50,750 1.60% ICU admission 1.58 (1.09–2.3)*
Lee et al. (14) Cohort study 7,160 NA SARS-CoV-2 infection 1.00 (0.93–1.08)*
Lee et al. (14) Cohort Study 7160 NA Composite 2.27 (1.50–3.41)*
Wang et al (15). Retrospective 61,783,950 NA SARS-CoV-2 infection 7.34 (6.65 −8.10)*
Ji et al. (16) Retrospective 219,961 3.6% SARS-CoV-2 infection 1.6–1.7 (ORR)
Nemani et al. (17) Retrospective 7,348 1%** In-hospital mortality 2.67 (1.48–4.8)*
Taquet et al. (18) Retrospective 62,354 2% SARS-CoV-2 infection 1.17 (1.02–1.33)*
Composite, Death or ICU admission or invasive ventilation; ICU, Intensive care unit; NA, Not given; *Odds ratio (95% CI); **Schizophrenia spectrum disorder; ORR, Odds ratio range
(95% CI not given).
or invasive ventilation or admission to ICU) from COVID-19
(AOR 1·3, 95% CI 1·0–1·7) (15). A propensity score matched
nationwide cohort study reported that patients with SMD
including schizophrenia are more likely to experience severe
COVID-19 outcome (ICU admission, invasive ventilation, or
death) compared to those without mental illness (AOR 2.27,
95% CI 1·50–3.41) (14). A separate case-control study also
reported that schizophrenia was independently associated with
severe SARS-COV-2 infection (odds ratio range, 1.206–1.645),
further suggestive of an intrinsic link between schizophrenia and
SARS-CoV-2 infection (16). Furthermore, a recent retrospective
cohort study reported higher risk of mortality [[OR], 2.67;
95% CI, 1.48–4.80] in patients with schizophrenia spectrum
disorder (17). Strikingly, in this study, schizophrenia was
reported to be the second-highest risk factor for COVID-19
mortality, after age, followed by other comorbidities such as
heart failure [OR = 1.60, 95% CI (1.43–2.00)], hypertension
[OR = 1.38, 95% CI (1.12–1.70)], diabetes [OR = 1.27, 95%
CI, (1.07–1.51)] and cancer [OR = 1.01, 95% CI, (0.85–
1.22)]. It is noteworthy that all the study estimates described
above were adjusted for potential confounders, including age,
gender and chronic medical comorbidities such as CVD, DM,
COPD, cancer etc. Finally, the UK Care Quality Commission
has also highlighted higher COVID-19 related death rates in
institutionalised populations with mental illness (29). Together,
these findings indicate that people with schizophrenia may carry
both an inherent vulnerability toward COVID-19, and increased
risk of more adverse clinical outcomes.
Given the relative novelty of the SARS-CoV-2 virus,
unravelling and integration of biologically plausible links with
clinical SARS-COV-2 data is crucial in order to improve our
understanding of the pathophysiology of the disease.
SCHIZOPHRENIA AND COVID-19:
PROGNOSTIC FACTORS AND POTENTIAL
MECHANISMS
Age, Gender, and Ethnicity
The risk of SARS-CoV-2 infection and associated mortality
increases with age, with males more at risk of higher mortality
rates than females (30). The average age of patients with
schizophrenia hospitalised for COVID-19 is younger than the
general population (13). Moreover, a recent study has reported
that younger patients with comorbid schizophrenia (<55 years)
and COVID-19 had an increased risk of intensive care unit
(ICU) admissions (13). In addition, age may also interact
with schizophrenia liability for increased risk of SARS-CoV-2
infection. A recent case-control study reported that older adults
with schizophrenia (>65 years) had a higher risk of SARS-CoV-
2 infection than those aged 18–65 years (adjusted OR 1.74, 95%
CI:1.33–2.28, p < 0.001) (15).
The prevalence of COVID-19 in people with comorbid
schizophrenia is not dissimilar between the genders (49 and 51%
for males and females, respectively), while women had higher
death rates and less ICU admissions than men (13). This is
discrepant to the general population, where male gender is a risk
factor for ICU admission and mortality (31). In another study,
women with schizophrenia had higher incidence of SARS-CoV-2
infection than men (adjusted OR = 1.53, 95% CI: 1.21–1.94, p <
0.001) (15).
In the general population, mortality rates from SARS-CoV-2
infections among people from ethnic minorities are two to four
times higher than in the White European population (32). These
findings are echoed in the schizophrenia population. A recent
case-control study reported that, as compared to White patients,
African Americans with schizophrenia had higher prevalence of
SARS-CoV-2 infection (adjusted OR: 2.33, 95% CI 1.84–2.97, p
< 0.001 and higher mortality rates (6.2 vs. 3.7%, p < 0.001), with
men having higher mortality rates than women (6.6 vs. 3.4%, p <
0.001) (15).
Comorbidities
The risk factors for severe SARS-CoV-2 infection such as CVD,
DM and chronic respiratory diseases such as COPD (4, 33), are
more common in people with schizophrenia than in the general
population (5, 6, 8). In patients tested positive for SARS-COV-2,
people with mental illness including schizophrenia had a greater
prevalence of concomitant medical comorbidities compared with
those without mental illness (diabetes 27.3 vs. 9.7%; CVD 15.5
vs. 4.9%; cerebrovascular disease 16.6 vs. 3.8%; COPD 11.2 vs.
3.3%; asthma 16 vs. 8.4%; hypertension 43.2 vs. 17.8%; chronic
kidney disease 5.8 vs. 3%) (14). A similar trend in comorbidities
Frontiers in Psychiatry | www.frontiersin.org 3 May 2021 | Volume 12 | Article 666067
Mohan et al. Mechanisms for COVID-19 Severity in Schizophrenia
(such as CVD, COPD, cancer, chronic kidney disease, and
asthma) was reported in another study (15). Importantly, the
increased risk of COVID-19 in patients with SMD remained after
adjusted analysis, suggesting that the underlying SMD itself could
directly contribute to the increased risk of COVID-19 infections
(15). In hospitalised COVID-19 patients with schizophrenia, the
prevalence of CVD was (23%), cerebrovascular disease (8%),
COPD (15%), diabetes (25%), dementia (25%), cancer (6%), and
renal disease (12%) compared to those without schizophrenia
(29, 6, 13, 28, 9, and 14%, respectively) (13). The prevalence
for CVD was higher among younger patients (<55 years)
who also had more ICU admissions (13). Moreover, in people
with schizophrenia, non-survivors had greater prevalence of
comorbidities than survivors (renal disease 20.3% vs. 9.8%;
hemiplegia 5.4 vs. 3.9%; peripheral vascular disease 9.2 vs. 4.7%;
Metastases 6.2 vs. 2.1%; Cancer 15.1 vs. 7.1%; diabetes with
complication 9.3 vs. 5.3%; diabetes without complications 25.6
vs. 20.6%; dementia 16.7 vs. 7.9%; cerebrovascular disease 10.1
vs. 5.2%; COPD 14.8 vs. 12.1%; congestive heart failure 27.4 vs.
13%; myocardial infarction 12 vs. 6.1%) (13). All these studies
reported a greater risk of mortality after adjusting for potential
cofounders (including age, gender and physical comorbidities),
suggesting that schizophrenia may independently contribute to
poor prognosis in COVID-19.
Pathological Immune Response in
Schizophrenia and COVID-19 Infections
A potential mechanism linking schizophrenia to more severe
SARS-CoV-2 infection is the dysregulated immune system (34–
36). Circulating levels of inflammatory biomarkers (including
interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α),
C-reactive protein (CRP), growth differentiation factor 15
(GDF-15) and D-dimer are often significantly elevated in
severe SARS-CoV-2 infection and have been associated with
increased risk of mortality (34, 37, 38). In COVID-19, this
cytokine overproduction can lead to cytokine storm leading
to adverse clinical outcomes such as multiorgan failure and
deaths (39).
Several studies have reported that, both chronic schizophrenia
and drug-naive first-episode psychosis (FEP) are characterised
by a systemic pro-inflammatory state, as evidenced by higher
levels of proinflammatory biomarkers such as IL-1β, IL-6,
TNF-α, GDF-15, and CRP (7, 40–45). Importantly, high levels
of pro-inflammatory cytokines have been reported in the
cerebrospinal fluid and serum of people with schizophrenia
(46), implicating that inflammatory changes measured in the
periphery may mirror those found in CNS. In addition, various
neurological manifestations have also been implicated in SARS-
CoV-2 infections that can result in a dysregulated CNS immune
response (47, 48). This neurotropism of SARS-CoV-2 is often
attributed to structural and functional brain changes, especially
glial cells and astrocytes, which orchestrate innate immunity
in the brain (49). Glial cell dysfunction (50–52), particularly
chronic activation of microglial cells (53), is a common feature
in the pathophysiology of schizophrenia, and is associated with
deleterious proinflammatory effects (53).
Given the central role of immune dysregulation in developing
fatal SARS-CoV-2 infections, and that schizophrenia is already
characterised by subclinical inflammation, the systemic hyper-
inflammation triggered by SARS-CoV-2 infection may be more
pronounced in people with schizophrenia. These exacerbated
proinflammatory responses can trigger systemic tissue damage
and multiorgan failure. It is to be noted that high concentrations
of inflammatory biomarkers such as CRP (>200 mg/L) and
ferritin (>2,500 ng/mL) at admission have been found to be
strong predictors of COVID-19 severity (54). Similar conclusions
can also be drawn from a recent study, where patients
with SMD including schizophrenia who were hospitalised for
severe COVID-19 had high levels of inflammatory biomarkers
such as CRP, IL-6, D-dimer and ferritin, on admission (54,
55). Furthermore, a relationship exists between lymphocyte
subpopulations such as the natural killer (NK) cells that
contribute to early antiviral immunity, and schizophrenia.
Natural killer cell depletion is a common finding both in people
with schizophrenia (56) and in severe COVID-19 (57). Higher
viral loads can attenuate the immune response in people with
schizophrenia due to reducedNK activity, exposing them tomore
severe infection. This might, at least in part, help to explain why
people with schizophrenia are more susceptible to COVID-19
and experience worse clinical outcome, as compared to general
population. Taken together, these findings imply that changes
in pathways which regulate immunomodulation could be one
of the mechanism linking schizophrenia and severe COVID-
19. Since people with schizophrenia are already in a state of
hyperinflammation, a profound inflammatory response to SARS-
CoV-2 infection could trigger adverse clinical outcomes and
contribute to an increased risk of mortality from COVID-19.
Antipsychotic Use and Immunodeficiency
Another potential mechanism linking schizophrenia with an
increased risk of poor COVID-19 clinical outcomes might be
attributable to the use of antipsychotics. There is some evidence
to suggest that exposure to antipsychotic therapy is associated
with increased risk of respiratory infections such as pneumonia,
and thromboembolism (58, 59), both of which are fatal clinical
manifestations of COVID-19 (60). Antipsychotics, especially
clozapine are associated with an increased risk of agranulocytosis
and blood dyscrasias, and therefore an increased vulnerability
to infections (61, 62). A few studies have investigated the
effects of antipsychotic prescribing on COVID-19 outcomes.
A recent retrospective cohort study reported that clozapine
was associated with increased risk of SARS-CoV-2 infection
compared with other antipsychotic medications (adjusted HR
= 1.76, 95% CI 1.14–2.72) (63). A recent systematic review
recommended careful monitoring of clozapine in COVID-19
patients (64). Another atypical antipsychotic, risperidone has
been shown to be associated with global immunosuppression
and increased susceptibility to infections (65). While the clinical
data regarding the safety of risperidone in COVID-19 is sparse,
preclinical studies have reported a direct deleterious effect of
risperidone on inflammatory and immune process regulation
(66). In the premise of inflammatory storm and consequent
higher mortality rates in COVID-19, this observation may be
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worth considering in risk prognostication. Furthermore, recent
reports on haloperidol on COVID-19 outcomes are varied. An
observational study reported no association between haloperidol
prescribing and risk of intubation, death or discharge time
among patients hospitalised for COVID-19 (50). In contrast,
neuroleptic malignant syndrome, which is typically associated
with antipsychotics, has been reported in a case-study of a
middle aged male with comorbid schizophrenia and severe
COVID-19, who was prescribed haloperidol (51). In addition,
COPD is very common in patients with schizophrenia (8),
and antipsychotic use is associated with an increased risk
of acute respiratory failure in people who have COPD (52).
Furthermore, antipsychotics have been shown to be associated
with an elevated risk of thrombotic events (58, 67). COVID-
19 is associated with coagulation abnormalites, that can lead to
fatal thromboembolic events (68–71). Therefore, once infected,
the risk of thromboembolic events may be more pronounced
in people prescribed antipsychotics. The evidence to date on
the association between antipsychotics and COVID-19 are
predominantly from observational studies and case reports,
therefore further studies are warranted to clarify whether
antipsychotics could have a detrimental effect on the SARS-
CoV-2 clinical course. However, based on our knowledge on the
pharmacology of antipsychotics, and after taking into account
of the evidence presented above, it is worth considering that
some classes of antipsychotics may carry an increased risk of
poor prognosis in patients with COVID-19. In line with this
hypothesis, a recent review of evidence by an international,
multi-disciplinary working group of experts reported that
antipsychotics may carry an increased risk of worsening
respiratory function and thromboembolism in patients with
COVID-19, and proposed practical recommendations for the
clinical management of psychotropics in patients with COVID-
19 (72).
Obesity
Obesity, especially abdominal obesity, is a well-acknowledged
comorbidity among patients with chronic schizophrenia (7, 73),
and is a strong risk factor for susceptibility, transmission and
severity of COVID-19 (74, 75). In a recent meta-analysis of
COVID-19 studies, obesity was associated with high morbidity
and mortality rates, and increased ICU admission rates (76).
Pertinent to these observations, a recent study reported that
obese patients with comorbid schizophrenia had 14% more
ICU admissions than controls (13). Several mechanisms can
proposed by which obesity could contribute to increased
susceptibility, transmission and poor COVID-19 outcome in
people schizophrenia.
First, as mentioned earlier, obesity is highly prevalent
in people with chronic schizophrenia (8), and ACE2 gene
expression has been reported to be higher in visceral and
subcutaneous adipose tissue than in lung tissues (59). ACE2
is the principal cellular entry receptor for SARS-CoV-2 (77),
and this mechanism may suggest a high viral propagation in
people with schizophrenia who are obese (78). The adipose tissue
may, therefore act as a viral reservoir, contributing to prolonged
viral shedding (79), and a more contagious state in people
with schizophrenia. Second, both schizophrenia and obesity are
characterised by dysregulated immune response to infections,
contributing to increased susceptibility to infections (34–36).
The immunomodulatory effects of obesity that can impair key
immune response to SARS-CoV-2 is well-acknowledged (74).
Third, obesity also contributes to diminished lung function and
life threatening thrombolytic events in COVID-19 patients (74).
Although old age is one of the major risk factors for severe SARS-
CoV-2 infection, young individuals with schizophrenia who are
also obese may be at risk of greater severity of COVID-19, than
their peers. A recent study reported that schizophrenia patients
under 55 years, who were predominantly obese had 14% higher
risk for more ICU admissions than controls (13). Furthermore,
individuals with obesity and schizophrenia have lower vitamin
D concentrations, which could also impair immune response
(80, 81). There is mounting evidence that vitamin D deficiency
could be a risk factor for adverse COVID-19 outcomes (81),
and the efficacy of vitamin D supplementation in reducing risk
and/or severity of COVID-19 is currently being investigated
in randomised controlled trials. Taken together, these findings
suggest that obesity might also be a strong risk factor for adverse
clinical outcomes in patients with schizophrenia.
COVID-19, Coagulopathies, and
Schizophrenia
In severe cases of COVID-19, fatal coagulation abnormalities
that can be life-threatening, has been widely reported (68–71).
More recent researches have highlighted the coagulation cascade
in COVID-19 through mechanisms (possible synergistic) such as
endothelial dysfunction, systemic inflammation, tissue damage,
platelet activation and hypoxic vasoconstriction, resulting in fatal
thromboembolic events (82). Moreover, impaired fibrinolysis, as
evidenced by higher levels of plasminogen activator inhibitor
(PAI-1), has been reported in patients with COVID-19, which
could further elevate the thrombotic risk (83). Most patients with
severe COVID-19 and coagulopathy presents with an increased
concertation PAI-1 and D-dimer, which are also associated
with fatal thrombotic complications (83, 84). Furthermore,
anticoagulant therapy appears to confer prognostic benefit in
severe COVID-19 patients (85).
There is evidence to suggest that schizophrenia may be
a hypercoagulable state, due to the underlying inherent
pathobiological process (86–88) and antipsychotic medication
(67, 89, 90). Importantly, increased levels of PAI-1 have been
reported in people with schizophrenia than controls (91),
suggesting an imbalance between clotting factors and fibrinolysis.
In a retrospective study from New York City, elevated levels
of prothrombotic markers such as D-dimer was reported
among hospitalised patients with severe COVID-19 and mental
illness including schizophrenia (55). Given that coagulation
abnormalities may be associated with both schizophrenia and
SARS-CoV-2 infections, the coexistence of these conditions
might confer a cumulative risk of thromboembolic events.
The precise mechanisms underlying hypercoagulation
in patients with schizophrenia and COVID-19 are unclear.
However, taking available evidence into account, we hypothesise
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that dysregulated immune response, obesity and endothelial
damage/dysfunction, which are common in schizophrenia
(92–94) and severe COVID-19 (95), might predispose people
with schizophrenia to a higher risk of thromboembolic
events, once infected with SARS-CoV-2. Taken together, it is
reasonable to assess the risk of thromboembolic events and to
consider thromboprophylaxis in people with schizophrenia,
if they are hospitalised with COVID-19. Prospective studies
are warranted to validate the efficacy of anticoagulation
therapy in preventing thrombotic events in this group
of patients.
Non-diabetic Hyperglycemia
While underlying DM is considered a strong risk factor for
increased COVID-19 disease severity and higher mortality
(96), recent evidence suggest that prediabetes (non-diabetic
hyperglycemia or intermediate hyperglycemia) is also associated
with the severity of COVID-19. A prospective study from
a large suburban hospital from New Jersey reported that in
COVID-19 patients, prediabetes was independently associated
with intubation (97). A retrospective study from China reported
that impaired fasting glucose was an independent predictor
for 28-days mortality in COVID-19 patients without DM (98).
Similarly, another study of hospitalized COVID-19 patients, pre-
existing prediabetes was associated with higher risk of mortality,
compared with those with normoglycemia (99). Moreover,
previous studies have reported a positive association between
prediabetes and inflammatory biomarkers that are involved in the
severity of COVID-19, such as CRP and IL-6 (100, 101).
The foregoing findings may carry important clinical
implications in schizophrenia. There is evidence to suggest an
intrinsic link between disrupted glucose-insulin homeostasis
and schizophrenia. For instance, recent evidence from
a population-representative birth cohort has found that
disrupted glucose-insulin homeostasis from mid-childhood is
longitudinally associated with psychosis in adulthood in a dose-
dependent manner, even after adjustment for a detailed range
of sociodemographic and lifestyle confounders. Furthermore,
meta-analysis have reported that non-diabetic hyperglycemia
(such as insulin resistance and prediabetes) is highly prevalent in
antipsychotic naïve patients with schizophrenia, compared with
matched controls (9, 102).
Both diabetes and prediabetes are characterised by impaired
insulin secretion and insulin resistance (100). Notably, the
main pathophysiological mechanisms implicated in the severity
of SARS-CoV-2 infection, including dysregulated immune
responses, innate immune defects, reduced adaptive immunity to
infections and hypercoagulable state (11), also characterise both
prediabetes (100), and schizophrenia, as stated already. Indeed,
recent evidence from a Mendelian randomization study suggests
that inflammation may be a common biological mechanism for
comorbid insulin resistance and schizophrenia (103). Although
prediabetes is not conventionally viewed as a comorbidity,
preliminary evidence suggest that pre-diabetes could be a risk
factor for severe COVID-19, and this risk may be magnified in
people with schizophrenia as glucose homeostasis is impaired,
even in drug naïve people with schizophrenia (102). Large studies
are required to investigate this relationship further in the context
of schizophrenia.
TREATMENT FOR EARLY COVID-19 IN
SCHIZOPHRENIA—A CRITICAL NEED
People with schizophrenia represent a highly vulnerable
population, whose immune response may be diminished than
general population. The early- onset infection with SARS-
CoV-2 is purported to be mild (104), providing a potential
window for early interventions, aimed at prevention of disease
progression and reducing the risk of hospitalization and deaths.
While there are effective therapeutic options available for
moderately to severely ill hospitalized COVID-19 patients, such
as remdesivir and dexamethasone (105, 106), effective treatment
modalities for early COVID-19 (mild to moderate disease) have
been more elusive. Remdesivir does not appear to offer any
significant clinical benefit for patients with mild or moderately
severe COVID-19 who are without respiratory support, and
the National Institute for Health and Care Excellence (NICE)
do not recommend its use in this group of patients (107).
Dexamethasone is yet to be tested in early covid-19, and its
immune-suppressive effects warrants caution when prescribed
to people with schizophrenia, as it may inadvertently lead to
poor treatment outcomes (108, 109). Due to the multifaceted
pathophysiology of the SARS-CoV-2 virus, no single proven
therapeutic agent exists to date. An ideal early therapeutic option
in this group of patients may be the one that can address
the principal components of infection severity that are shared
between schizophrenia and COVID-19, such as cardiometabolic
factors (e.g., obesity and prediabetes), hypercoagulable state,
and inflammation (110). In this context, accruing evidence
from pilot RCTs and observational studies have reported
mortality benefits for antiplatelet and anticoagulant agents such
as aspirin and heparin, non-steroidal anti-mitotic drug such as
colchicine and oral hypoglycaemic agents such as metformin,
in a diverse population with COVID-19 (110–112). All of
these agents are already proven clinically safe and are in use
for treating other conditions. However, rigorous well-powered
clinical trials will be needed to ascertain the effectiveness of
such treatments for patients with schizophrenia. Finally, it is
important to consider potential drug-drug interactions (DDI)
with COVID-19 medications and antipsychotics. Such DDIs
can result in either reduced drug tolerance reduced efficacy
or reduced safety. A recent systematic review involving three
drug interaction databases reported risk of QT-prolongation
and Torsade de Pointes, and cytochromes P450, as major
interactions between COVID-19 drugs and antipsychotics (113).
This systematic review suggests a high risk of DDI between
lopinavir/ritonavir plus quetiapine and ritonavir/indinavir plus
risperidone, hematological risk with clozapine and baricinitib,
caution for favipiravir plus chlorpromazine and quetiapine,
while no DDI risk was associated with remdesivir, baricinitib,
tocilizumab and anakinra (113).
Irrespective of the proposed treatment regimen, given that
COVID-19 is transmitted through droplet and aerosol spread,
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a period of self-isolation will always be required. Studies have
shown that self-isolation can lead to substantial psychological
burden in people with schizophrenia (114, 115). In addition,
such self-isolation may impede the patient from receiving
their usual antipsychotic treatment, particularly in instances
where treatment is provider administered, such as with long
acting injectable antipsychotics; or in instances where relatively
intensive monitoring is required, such as with clozapine.
Delays or disruption in receiving antipsychotic medications may
increase the risk of psychosis relapse (116). The Royal College
of Psychiatrists in the UK has now provided specific guidance
regarding psychotropic treatment in people with a positive
COVID-19 diagnosis (117).
DISCUSSION
In this article, we have summarised the effect of COVID-19
in patients with schizophrenia, and the potential mechanisms
which may underly poor COVID-19 prognosis in people
with schizophrenia. The current evidence suggests that people
with schizophrenia may be at increased risk of mortality
and morbidity from COVID-19. Although this reduced life
expectancy was thought to be due to coexisting comorbidities
such as CVD, DM and hypertension, all these studies have
adjusted for the aforementioned comorbid conditions, as well
as other prognostic factors such as age, sex and race. This
suggests that schizophrenia “per-se” may have an inherent
pathophysiological association with COVID-19. Although the
exact mechanisms of the poor prognosis is yet to be fully
elucidated, there are tentative clues which suggest that this
is likely to be multifactorial due to the syndromic nature of
schizophrenia (Figure 1). However, a closer look at the data
suggests a more complex picture, as the majority of studies did
not factor in various other relevant social determinants such as
deprivation, poverty and homelessness, all of which are more
common in people with schizophrenia, and are also associated
with worse outcomes in COVID-19. Therefore, thoughtful
assessment of the various factors that contribute to poor COVID-
19 prognosis in people with schizophrenia will be crucial to
improved patient care.
These emerging observationsmay have implications for future
research and for the management of people with schizophrenia.
First, with respect to research, predictive instruments for those
most at risk of severe outcomes should consider schizophrenia.
For instance, in UK, the National Health Service uses a risk
prediction algorithm based on age, ethnicity, deprivation, body
mass index, and a range of comorbidities including severe
mental illness not just limited to schizophrenia, known as
the QCOVID (118). Second, a clearer understanding of the
complex pathophysiological mechanisms linking COVID-19
with schizophrenia may provide insights for: (i) clinicians in
patient management; (ii) developing preventive measures against
COVID-19; and (iii) developing effective therapeutic strategies
to potentially reduce the risk of developing severe COVID-19
illness. Furthermore, to facilitate early intervention for COVID-
19, more research is warranted to investigate the DDIs between
potential COVID-19 treatments and anti-psychotics. Finally,
the present definition of ‘clinically extremely vulnerable’ for
vaccine prioritisation, does not include patients with SMD (119).
Therefore, taking into account of the higher vulnerability to
severe COVID-19 infections and increased mortality in people
with schizophrenia, it is paramount that COVID-19 vaccine
allocation should also be prioritised for this group of patients.
Our knowledge of the public health consequences of
SARS-CoV-2 infection in patients with schizophrenia at this
early stage is limited. Clinical management of COVID-19
in this group of patients may pose a clinical challenge to
clinicians. Further research is needed from resource-limited
settings such as low-and-middle-income countries (LMIC) to fill
knowledge gaps about the epidemiology, clinical characteristics,
incidence, mortality and morbidity of COVID-19 in people
with schizophrenia. There is a paucity of COVID-19 outcome
data from LMICs where health inequalities and treatment
gaps are much wider than high income countries. The
epidemiological studies included in this article were primarily
conducted in high income countries, thus limiting the clinical
observations generalisable to LMICs. Moreover, the majority of
the LMICs have a younger population with a high prevalence
of cardiometabolic diseases compared to high income countries,
which makes the effects of pandemic even more dire. Finally, the
bidirectional relationship between COVID-19 and psychiatric
disorder (18) should bolster further research to elucidate
the mechanisms by which SARS-CoV-2 (e.g., neurotropism)
might contribute to psychiatric sequela. Previous studies from
prospective birth cohorts have shown longitudinal associations
between inflammation and psychosis (120–122), suggesting that
abnormal inflammation may increase the risk of psychosis.
Findings fromMendelian randomization also support a potential
causal role of inflammation on schizophrenia pathogenesis and
comorbid schizophrenia (123).
Of note, we acknowledge the limitations of this hypothetical
article. First, given the heterogeneity of the literature and
the broad research question we have sought to tackle, a
systematic review or meta-analytic approach was not possible.
Second, given the large volume and rapid nature of COVID-
19 research, we have discussed and cited data from preprint
reports on bioRxiv along with peer-reviewed manuscripts.
Therefore, these findings should be interpreted with caution.
Third, the data on COVID-19 and schizophrenia are derived
from non-randomised, observational studies, and we recognise
the inherent limitations of such studies. However, the large
sample sizes of some studies and robust statistical methods used
(case-control studies, propensity score–matched cohort analyses
etc), may have helped limit the potential biases and residual
cofounding influences. Finally, evidence about SARS-CoV-2 is
rapidly evolving, therefore the findings of this article might vary
as the understanding of SARS-CoV-2 progresses.
In conclusion, it appears that SARS-CoV-2 infections are
not just confined to cardio-respiratory system, but can also be
linked to neuropsychiatric diseases. The findings discussed in
this article indicate that people with schizophrenia may confer
an inherent risk for COVID-19 related morbidity and mortality,
irrespective of underlying comorbidities. Therefore, the notion
that people with schizophrenia will already be covered by current
vaccine rollout strategies due to their coexisting comorbidities
is highly debatable. Given the lack of proven treatment for
Frontiers in Psychiatry | www.frontiersin.org 7 May 2021 | Volume 12 | Article 666067
Mohan et al. Mechanisms for COVID-19 Severity in Schizophrenia
FIGURE 1 | Hypothetical pathogenesis linking schizophrenia to severe Covid-19 infections.
COVID-19 and with efficacious COVID-19 vaccines now
available, we recommend that this group of patients should be
prioritised to receive COVID-19 vaccines. In this article, we
have provided a snapshot of potential pathophysiological links
between SARS-CoV-2 pathogenesis and schizophrenia, which
may increase the risk of more severe outcomes. We propose that
such closely interlinked prognostic components must certainly
not be overlooked. To meet the urgent need for effective
treatment, an integrated public health approach must be made
by researchers globally, to investigate and report, the clinical
and pathophysiological underpinnings that drive this clinical
deterioration. Finally, emerging evidence suggest an increased
incidence of neuropsychiatric complications following COVID-
19, including mental disorders such as psychosis. Therefore,
special attention should be given to the psychiatric aspects
of COVID-19.
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